Biogen Gets Attys' Fees In Classen Immunization IP Row
A Maryland federal judge on Wednesday found that Classen Immunotherapies Inc.'s claims that Biogen Idec Inc. infringed its patents for evaluating a vaccine immunization schedule were objectively baseless, dismissing Biogen from...To view the full article, register now.
Already a subscriber? Click here to view full article